Systematic review on screening the role of chemosensitizer or synergistic drug and doxorubicin as dual drug loaded nanoparticle in overcoming multidrug resistant breast cancer

Abstract

Doxorubicin (DOX) is a widely used anticancer drug. Outspread and prolonged usage results in the development of multidrug resistance (MDR). Marry of a chemosensitizer/synergistic drug (CZ/SD) and DOX with a suitable drug delivery platform helped to overcome this problem. In this context, this study is framed to screen the role of chemosensitizer/synergistic drug and DOX as dual drug-loaded nanoparticles (NPs) in overcoming MDR breast cancer. To conduct a literature search authors used the following mesh terms: 'doxorubicin' and 'breast neoplasms' and 'nanoparticles' and 'drug resistance, multiple' and non-mesh terms such as 'dual drug' or 'codelivery' or 'coloaded' or 'coencapsulated' in different databases such as PubMed, google scholar, Science direct and Springer. These databases explored titles and abstracts of original research articles from inception to Jul 2020. This search identified a total of 44 papers. Three duplicate records are removed from these 44 papers. The remaining 41 records were screened by following their titles and abstracts. From 41 records, 14 removed as they were not fulfilling the eligibility criteria of the present study design. After removing sixteen articles (not satisfy inclusion criteria), finally eleven articles were included in this systematic review. This systematic review summarizes the enhanced chemotherapeutic effect of DOX in both in vitro and in vivo MDR cancer models. This improved efficacy of DOX was due to the simultaneous codelivery of DOX and CZ/SD by using a suitable drug delivery platform. In a word, this review emphasizes to move onward to conduct a meta-analysis of similar reported studies.